Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India

BACKGROUND: A new, oral fixed dose combination of highly selective neurokinin-1 receptor antagonist, netupitant with 5HT3 receptor antagonist, netupitant and palonosetron (NEPA) was approved in India for prevention of chemotherapy induced nausea and vomiting (CINV). AIM: To assess effectiveness of N...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaswani, Bharat, Bhagat, Sagar, Patil, Saiprasad, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443837/
https://www.ncbi.nlm.nih.gov/pubmed/32879847
http://dx.doi.org/10.5306/wjco.v11.i8.606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443837/
https://www.ncbi.nlm.nih.gov/pubmed/32879847
http://dx.doi.org/10.5306/wjco.v11.i8.606

Ejemplares similares